16.11.2026 12:03

Research breakthroughs advance Type 1 diabetes cell therapy

Irland University of Galway Autor nicht angegeben
Two University of Galway studies have developed methods to protect insulin-producing cells during transport, a challenge for cell therapies being investigated for Type 1 diabetes. One uses a vitamin C hydrogel, which improved cells’ insulin response by about 41 per cent in laboratory tests; the other is an oxygen-supplying device that kept cells shipped from Ireland to Italy at ambient temperature around 80 per cent viable after 48 hours. Researchers say testing with human islets and other patient-relevant cells is the next step.
KI-Zusammenfassung

Two University of Galway studies have developed approaches to protect insulin-producing cells during transport: a vitamin C hydrogel and an oxygen-supplying device. In tests, the device kept cells shipped from Ireland to Italy at ambient temperature around 80 per cent viable after 48 hours.

Research breakthroughs from Rinn Medical Devices at University of Galway are addressing a major obstacle for cell therapies as a potential treatment for Type 1 diabetes.

Two recent research studies have found a way to keep fragile insulin-producing cells alive and functional between their manufacture and delivery to patients.

Historically, these cells often perish during transportation due to exposure to harmful oxidants that lead to cell damage.

In the first study, published in the Journal of Materials Chemistry B, Dr Amir Alsharabasy and Professor Abhay Pandit set out how their research has developed a new vitamin C hydrogel to protect insulin-producing cells.

The team attached vitamin C to hyaluronan, a natural substance found in the body's tissues. In laboratory tests, lab-grown insulin-producing cells that were exposed to harmful oxidants had healthier energy production when protected by the gel. The cells also released about 41 per cent more insulin in response to glucose than cells in a standard gel, and showed fewer signs of stress during storage.

Dr Amir Alsharabasy, Rinn Medical Devices, University of Galway, said: "Cells that make insulin are very easily damaged by oxidative stress when they are handled and stored. By building vitamin C into the gel itself, the protection stays right next to the cells instead of washing away."

Professor Abhay Pandit, Director of Rinn Medical Devices at University of Galway, said: "These are early but encouraging, laboratory-based results using cell lines. The next step is to test the gel with real insulin-producing cells and stem-cell-derived cells, which are much closer to what a patient would receive."

In another related study, scientists from University of Galway - Dr Daniel Domingo-Lopez, Dr Ruth Tarpey, Professor Garry Duffy and Dr Ruth Levey, published results of their research on the development of a new dual-chamber device that supplies oxygen to cells through a gas-permeable membrane in the Advanced Functional Materials journal.

Dr Ruth Levey, Institute for Health Discovery and Innovation, University of Galway, said: “Many of today's cell therapies have to be frozen and kept ultra-cold the whole way from the lab to the patient which needs specialist equipment, is expensive and can damage the cells. In practice, it means that access to these therapies is very limited. Our device keeps the cells fresh and supplied with oxygen, so they can travel using standard courier networks with the aim of making it easier for these therapies to reach more patients, wherever they live.”

Insulin-producing cells are particularly difficult to transport because they are highly sensitive to low oxygen and do not survive freezing well. As part of the study, insulin-producing cells shipped from Ireland to Italy at ambient temperature showed around 80 per cent viability after 48 hours and formed functional insulin-secreting clusters, unlike cells that had been frozen and thawed using standard transport methods. A computer model of how oxygen moves through the device, suggests one device could transport 2,000 to 2,500 human islets, the clusters of insulin-producing cells found in the pancreas, for 48 hours.

Professor Garry Duffy, Director of the ARC Hub for Healthtech and Principal Investigator at Rinn Medical Devices at University of Galway, said:: "Human islet validation is the essential next step, but we hope that the platform can be adapted to many cell types. For patients, higher-quality cells could mean more reliable treatments and, eventually, less reliance on insulin injections.

Professor Abhay Pandit added: "At Rinn Medical Devices, we bring materials scientists, engineers, biologists and industry partners together because no single field could solve this on its own. Both studies show what becomes possible when disciplines work side by side. One tackled a chemistry problem, protecting cells with a vitamin C-bonded gel. The other tackled an engineering problem, delivering oxygen during transport. Each group solved a different piece of the puzzle, and that is how promising ideas reach patients faster."

The work involved researchers from Rinn Medical Devices, the University of Galway's regenerative medicine institute REMEDI, the University of Limerick, Trinity College Dublin, RCSI and Explora Biotech in Rome, and was backed by Research Ireland and European funding.

Ends



https://www.universityofgalway.ie/about-us/news-and-events/news-archive/2026/november/research-breakthroughs-advance-type-1-diabetes-cell-therapy-1.html
Autor
Kontaktperson
Marketing and Communications

Unternehmen / Organisation
University of Galway
Herunterladen
Teilen
Galerie